Answers are grounded in this paper and cite their sources.
Immune checkpoint inhibitors (ICIs) are widely used to treat malignancies, but may cause clinically important immune-related adverse events, including interstitial lung disease (ILD). The present study clarified the reporting patterns and reported time-to-onset of suspected ICI-related ILD using the Japanese Adverse Drug Event Report database. Reports from April 2004 to March 2026 were analyzed. Disproportionality signals based on both reporting odds ratio and information component were detected for all evaluated ICIs, except cemiplimab. The median reported time-to-onset was within approximately 2-3 months for the main analyzable ICIs, and Weibull shape parameters indicated early failure patterns for most ICIs. After adjustments for age category, pre-existing ILD, and indication category, male sex was associated with a shorter reported time-to-onset for nivolumab, but not for the other ICIs analyzed. These results suggest that sex-related differences in reported time-to-onset may be present in suspected nivolumab-related ILD reports.
No takes yet. Share an insight, caveat, or question.
Ide et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: